Stepronin

Drug Profile

Stepronin

Alternative Names: Broncoplus; KY 01; Masor; Mucodil; Prostenoglycine; Tenoglycine; TS 5010680; TTPG

Latest Information Update: 23 Jan 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sigma-tau SpA
  • Developer GlaxoSmithKline; Kissei Pharmaceutical; Pierrel; Samil; Samjin Pharmaceutical Company; sigma-tau SpA
  • Class Amino acids; Antitussives; Expectorants
  • Mechanism of Action HIV replication inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bronchitis; Otorhinolaryngological infections
  • Discontinued Autoimmune disorders; Graft-versus-host disease; HIV infections; Transplant rejection

Most Recent Events

  • 27 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
  • 23 Jan 2001 Glaxo Wellcome has merged with SmithKline Beecham to form GlaxoSmithKline
  • 20 Jan 2000 Preclinical development for HIV infections treatment in Italy (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top